Gastroenterology and Hepatology Partner with SCCR on Hepatitis Research

Recent successes in the field of Hepatitis C research have prompted efforts to find effective treatments for a variety of liver diseases including Hepatitis B and non-alcoholic fatty liver disease among other chronic liver diseases. 

SCCR and the Division of Gastroenterology and Hepatology at Stanford are participating in multiple research studies concentrating on these areas, including the testing of novel agents to treat these disorders. Additionally, they are participating in registry studies to gain greater insights into these conditions. Nearly 100 patients have been enrolled in Stanford studies of Hepatitis B Virus (HBV), and the Division continues to enhance its efforts in these and other areas, including autoimmune and inherited liver diseases, as well as decompensated cirrhosis. 

Acknowledging the increasing attention on HBV and Hepatitis Delta Virus (HDV), Stanford hosted a successful symposium on HBV and HDV in conjunction with the November 2018 Liver Meeting, an annual international conference hosted by the American Association for the Study of Liver Diseases. Stanford’s hepatology symposium drew over 175 attendees and included physician researchers as well as representatives from the FDA, pharmaceutical companies, and other leading hepatology organizations across the globe. The symposium provided a platform for focused discussions regarding the current state and future direction of efforts to find effective treatments for Hepatitis B and D, topics that will likely involve further SCCR activity.

Since 2015, SCCR’s partnership with the division of gastroenterology and hepatology has helped the division’s research portfolio grow from 10 studies with two coordinators to more than 80 studies with 12 clinical research team members.